Extended Data Fig. 4: FGFR inhibition regulates enhancer landscape in TNBC cells.

a, MA plot of differentially regulated H3K27ac ChIP-seq peaks in CAL-120 cells treated with 12d infigratinib versus DMSO. Mean of normalized counts of each peak are plotted on the x-axis and log2 fold changes of differential peaks are plotted on the y-axis. Significantly changed peaks (FDR < 0.05) are marked in red. b, Heatmaps of ATAC-seq, H3K27ac and YAP ChIP-seq signals at regions of decreased chromatin accessibility (FDR < 0.01, Log2 fold change < -1.5, n = 2798) upon 12d infigratinib treatment. c, Genomic distribution of regions of increased chromatin accessibility upon 12d infigratinib treatment. d, Venn diagram depicting overlap between H3K27ac peaks (green) and YAP (blue) DNA binding peaks after 12d infigratinib treatment. e, YAP (blue) and H3k27ac (green) ChIP-seq tracks around YAP target gene FSTL1 in CAL120 cells in the presence of DMSO or infigratinib at indicated time points.